CMS expands coverage for verteporfin therapy

New York-The Centers for Medicare and Medicaid Services (CMS)-formerlythe Health Care Financing Administration-will begin reimbursing patientswho use verteporfin for injection (Visudyne) with occult choroidal neovascularization(CNV) lesions secondary to age-related macular degeneration (AMD).